Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-4,500
Closed -$245K 97
2022
Q2
$245K Hold
4,500
0.05% 85
2022
Q1
$245K Hold
4,500
0.04% 96
2021
Q4
$248K Hold
4,500
0.03% 106
2021
Q3
$215K Hold
4,500
0.03% 120
2021
Q2
$224K Hold
4,500
0.03% 116
2021
Q1
$201K Sell
4,500
-102
-2% -$4.63K 0.03% 114
2020
Q4
$212K Hold
4,602
0.03% 112
2020
Q3
$217K Sell
4,602
-120
-3% -$6.01K 0.04% 99
2020
Q2
$241K Buy
4,722
+120
+3% +$6.16K 0.04% 88
2020
Q1
$218K Hold
4,602
0.06% 81
2019
Q4
$270K Hold
4,602
0.04% 109
2019
Q3
$246K Hold
4,602
0.04% 106
2019
Q2
$230K Hold
4,602
0.04% 102
2019
Q1
$240K Buy
4,602
+102
+2% +$5.1K 0.05% 97
2018
Q4
$215K Hold
4,500
0.05% 96
2018
Q3
$226K Hold
4,500
0.04% 121
2018
Q2
$227K Hold
4,500
0.04% 119
2018
Q1
$220K Buy
+4,500
New +$210K 0.04% 122
2017
Q4
Sell
-4,638
Closed -$235K 135
2017
Q3
$235K Buy
4,638
+138
+3% +$7K 0.04% 120
2017
Q2
$243K Hold
4,500
0.04% 113
2017
Q1
$237K Hold
4,500
0.05% 114
2016
Q4
$217K Hold
4,500
0.04% 108
2016
Q3
$243K Hold
4,500
0.05% 109
2016
Q2
$244K Hold
4,500
0.05% 105
2016
Q1
$228K Hold
4,500
0.06% 100
2015
Q4
$227K Hold
4,500
0.05% 99
2015
Q3
$216K Hold
4,500
0.05% 98
2015
Q2
$234K Hold
4,500
0.05% 99
2015
Q1
$260K Hold
4,500
0.05% 97
2014
Q4
$240K Hold
4,500
0.04% 102
2014
Q3
$259K Hold
4,500
0.05% 95
2014
Q2
$301K Hold
4,500
0.05% 92
2014
Q1
$301K Hold
4,500
0.05% 86
2013
Q4
$300K Hold
4,500
0.06% 85
2013
Q3
$282K Hold
4,500
0.06% 77
2013
Q2
$281K Buy
+4,500
New +$286K 0.06% 70

Other funds holding GSK

Cadinha & Co's GSK Position: Q3 2022 in Review

Cadinha & Co sold out of GSK (GSK) in Q3 2022, closing a stake of 4,500 shares — an estimated $245K sold.

Cadinha & Co first reported a position in GSK in Q2 2013 and held it in 36 quarters. The position peaked at $301K in Q2 2014. 742 funds tracked by Wall St. Rank hold GSK as of Q3 2022.

  • Cadinha & Co reported no remaining GSK position as of Q3 2022 after selling out during the quarter.
  • Cadinha & Co sold 4,500 GSK shares in Q3 2022, an estimated $245K.
  • Cadinha & Co first reported a position in GSK in Q2 2013 and held it in 36 quarters.
  • Cadinha & Co's GSK position peaked at $301K in Q2 2014.
  • 742 funds tracked by Wall St. Rank held GSK as of Q3 2022.

Based on Cadinha & Co's 13F filing for Q3 2022, filed 21 Oct 2022.